|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
11
|
|
pubmed:dateCreated |
2007-6-4
|
|
pubmed:abstractText |
Breast cancer resistance protein (ABCG2) substantially limits the oral bioavailability of topotecan. Coadministration with elacridar, an inhibitor of breast cancer resistance protein-mediated drug transport, increases the bioavailability of topotecan. The aim of this study was to establish the lowest effective dose of elacridar to obtain maximum oral bioavailability of topotecan and to determine the optimal schedule of coadministration of oral topotecan and elacridar. In the second part of this study, dose-limiting toxicities and maximum tolerated dose of oral topotecan coadministered with elacridar, at a daily times five regimen administered every 21 days, were established.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
13
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
3276-85
|
|
pubmed:meshHeading |
pubmed-meshheading:17545533-ATP-Binding Cassette Transporters,
pubmed-meshheading:17545533-Acridines,
pubmed-meshheading:17545533-Administration, Oral,
pubmed-meshheading:17545533-Adult,
pubmed-meshheading:17545533-Aged,
pubmed-meshheading:17545533-Antineoplastic Agents,
pubmed-meshheading:17545533-Cohort Studies,
pubmed-meshheading:17545533-Female,
pubmed-meshheading:17545533-Humans,
pubmed-meshheading:17545533-Male,
pubmed-meshheading:17545533-Maximum Tolerated Dose,
pubmed-meshheading:17545533-Middle Aged,
pubmed-meshheading:17545533-Neoplasm Proteins,
pubmed-meshheading:17545533-Neoplasms,
pubmed-meshheading:17545533-Research Design,
pubmed-meshheading:17545533-Tetrahydroisoquinolines,
pubmed-meshheading:17545533-Topotecan
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
A phase I, randomized, open-label, parallel-cohort, dose-finding study of elacridar (GF120918) and oral topotecan in cancer patients.
|
|
pubmed:affiliation |
Division of Clinical Pharmacology, Department of Medical Oncology, Antoni van Leeuwenhoek Hospital/The Netherlands Cancer Institute, Amsterdam, the Netherlands.
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Clinical Trial, Phase I
|
